CBD for Headaches and Migraines: Is It Worth Trying and How to Use It
Does CBD help with headaches and migraines? A randomized study found no advantage of CBD over placebo. Check how to plan a trial and when to see a doctor.
15.8 percent of people worldwide experience headaches every day, and active headache disorders affect 52 percent of the population (Stovner et al., The Journal of Headache and Pain, 2022). With such a scale, any promise of relief finds an audience, and cannabidiol has occupied a place in search engines as a ready answer for several years. The title of this text promises two things: an assessment of whether it is worth trying and instructions for use. The second part is uncomfortable because no one has established CBD doses for headaches. Below you will find what can be said honestly: what the first randomized study showed, how headache types differ, which symptoms require urgent diagnostics, and how to plan your own trial.
KEY INFORMATION
• The arm with CBD did not outperform placebo in migraine attacks: 53 versus 47 percent relief after two hours (Schuster et al., Headache, 2026).
• The advantage was only shown by the combination of THC with cannabidiol, which is a different preparation than the oil from the store.
• CBD doses for headaches have not been established in any study, so ready-made protocols are fabricated.
• 30 mg of CBD increased the concentration of amitriptyline, a preventive medication for migraines and tension-type headaches (Gorbenko et al., 2026).
• Sudden, worst headache of your life is a reason for urgent diagnostics.
Does CBD alleviate headaches and migraines?
There is no evidence for this. In the first randomized study of cannabis for acute migraine attacks, the arm with a predominance of cannabidiol did not prove better than placebo in any of the three endpoints measured after two hours (Schuster et al., Headache, 2026).
The study involved 92 people who treated up to four attacks, each time with a different preparation, in an alternating double-blind design. Vaporized flower with 6 percent THC, flower with 11 percent CBD, a combination of both, and a placebo in the form of flower from which THC and cannabidiol were chemically removed were compared. Of the 247 registered attacks, relief after two hours was achieved in 67 percent of those treated with the combination of THC and CBD, in 69 percent after pure THC, in 53 percent after the CBD-rich flower, and in 47 percent after placebo. Only the first two results were statistically significant, and lasting relief after 24 and 48 hours was provided solely by the combination of THC with cannabidiol.
One result speaks in favor of cannabidiol in this study and should be stated honestly. After one hour, the arm with a predominance of CBD performed better than placebo in terms of pain relief (59 versus 37 percent) and the alleviation of the most bothersome symptom (41 versus 22 percent). After two hours, the advantage disappeared, and this two-hour measurement was planned by the authors as decisive. The one-hour result is therefore a premise for further research, not evidence of effectiveness.
The distinction that arises from this determines the rest of the text. Cannabidiol and cannabis are not synonyms. The flower contains dozens of cannabinoids, primarily THC, which is a psychoactive substance with a different receptor profile. When a study shows that vaporizing cannabis shortens an attack, it speaks of cannabis with THC, not a bottle of oil. The lack of evidence of effectiveness is not evidence of lack of effectiveness: no one has studied oral CBD in migraine prevention in a way that could resolve the matter in either direction.
What type of headache do you have and why does it change the answer?
Because studies on cannabis have focused on migraines, and migraines are a minority of headaches. Globally, migraines affect 14 percent of people, tension-type headaches 26 percent, and headaches for 15 or more days a month 4.6 percent (Stovner et al., The Journal of Headache and Pain, 2022).
| Type of Headache | How It Manifests | What Has Documented Effectiveness |
|---|---|---|
| migraine | unilateral, pulsating, lasts from 4 to 72 hours, worsens with movement, with nausea or photophobia | triptans in an attack, medication prevention, magnesium, riboflavin |
| tension-type headache | bilateral, pressing, without pulsation, does not worsen with movement | amitriptyline 100 mg, botulinum toxin in chronic form |
| medication overuse headache | 15 or more days with pain in a month with frequent acute medications | discontinuation of the medication and prevention under medical supervision |
| secondary headache | symptom of another disease, usually with an alarm signal from the list below | diagnostics of the cause, often urgent |
In the prevention of chronic tension-type headaches, a network meta-analysis of 35 randomized studies rated amitriptyline at a dose of 100 mg the highest, which in these studies reduced the number of days with pain by more than six per month (Tao et al., Annals of Medicine, 2026). The authors themselves temper this result: they rated the certainty of the evidence as low to very low with a high risk of error and high heterogeneity, and amitriptyline at this dose caused more adverse effects than placebo. Cannabidiol is not included in this comparison at all, as there are no studies to include it. If you do not have a diagnosis from a doctor, the first step is to obtain one, not to choose a preparation.
When does a headache require urgent diagnostics instead of a supplement?
When it has a feature indicating a secondary headache, that is, a symptom of another disease. Fifteen such alarm signals have been collected in the SNNOOP10 list, developed to increase the chances of detecting a headache with a secondary cause (Do et al., Neurology, 2019). The authors note that there is a lack of prospective studies on the value of the signals themselves, so the list is a screening tool, not a diagnosis.
| Alarm Signal | What It May Indicate |
|---|---|
| sudden pain reaching a peak in seconds, the worst in life | subarachnoid hemorrhage, arterial dissection |
| fever with neck stiffness | meningitis or encephalitis |
| neurological deficit or altered consciousness | stroke, tumor, compressive process |
| pain that appeared after a head injury | intracranial hematoma |
| first severe headache in life after age 50 | giant cell arteritis, intracranial change |
| change in the previous character of pain, worsening from week to week | neoplastic process, intracranial hypertension |
The first item on this list is an emergency situation, not a reason to wait it out. The same applies to pain with fever and neck stiffness and any pain with a persistent neurological deficit. In these scenarios, the appropriate solution is the emergency number, and oil has no role here. Separately, it is worth counting the days in a month when you reach for any pain medication or triptan. Medication overuse headache is diagnosed precisely by this number, not by the intensity of pain, so a calendar with acute medications is more important here than any supplement.
How much CBD should I take for a headache?
No one has established this dosage. There is no clinical study comparing oral cannabidiol doses for migraines or tension-type headaches, so any protocol like “start with 10 mg and increase every three days to 60 mg” comes from the author of the text or from a seller, not from the literature.
The only dose actually tested in migraines was inhaled: vaporized flower with 11 percent cannabidiol, administered once during an attack. This variant did not outperform placebo. Transferring it to sublingual drops has no basis, as the route of administration changes pharmacokinetics.
It is not even known how much cannabidiol from the oil reaches the bloodstream. A systematic review of the pharmacokinetics of CBD in humans found only 24 studies with such data, and absolute bioavailability was measured only for smoking and was 31 percent (Millar et al., Frontiers in Pharmacology, 2018). For oral and sublingual administration, such values have not been established, as no study has compared these routes with intravenous administration. The “13 to 19 percent” circulating in store guides is indeed in this review, but in the introduction and in a different meaning: as a citation of an older work by Mechoulam from 2002, based on, among other things, animal studies. Citing this number as a measurement in humans is therefore an abuse, although the source address is correct.
This has practical consequences. The maximum concentration after swallowing appears in a window of up to four hours, so you cannot plan the intake of oil “at the first signs of an attack” with reasonable precision. More about routes of administration is discussed in the text about how to take CBD.
However, the upper limit is known. The EFSA panel on nutrition established a provisional safe dose of cannabidiol in 2026 at 0.0275 mg per kilogram of body weight per day, or about 2 mg per day for a person weighing 70 kg, taking into account an uncertainty factor of 400 (EFSA NDA Panel, EFSA Journal, 2026). This value applies only to supplements with a purity of cannabidiol of at least 98 percent, without nanoparticles. The same panel states that the safety of cannabidiol cannot be established in individuals under 25 years of age, in pregnant and breastfeeding women, and in individuals taking medications simultaneously. A person with migraines on medication prevention belongs to the latter group.
How to plan a CBD trial so that its result means something?
Establish an assessment criterion before the first dose, otherwise you will assess your mood, not the effect of the preparation. The criterion should be numerical and recorded in advance: we propose a reduction in the number of days with pain by at least one third after eight to twelve weeks. This is our working proposal, not a threshold from guidelines, but it has the advantage of being decisive rather than allowing for negotiations with yourself.
Start with a month of observation without any changes. Record the date of the attack, duration, intensity on a scale from 0 to 10, and every day you reached for acute medication. Only having such a base, introduce one thing at a time. If you simultaneously start cannabidiol, magnesium, and a new sleep rhythm, after two months you will not learn anything about any of them.
Write down the date of the decision in advance and stick to it. After eight, at most twelve weeks, compare the number of days with headaches to the baseline month. If the decrease does not reach the previously accepted one third, that is the answer. Increasing the dose just in case has no support here, as no dose-response relationship has been measured for cannabidiol in headaches.
Our observations from conversations with readers: the most often overlooked column in such a diary is the number of days with acute medication, and it is this that carries the most information. Those who report “milder attacks” with an unchanged number of days with a pill usually describe a change in well-being, not the course of the disease.
Does CBD interact with headache medications?
One interaction has been measured in humans and concerns amitriptyline. A single dose of 30 mg of cannabidiol increased the area under the concentration curve of amitriptyline by 13 percent, and the maximum concentration by 17 percent in healthy volunteers (Gorbenko et al., British Journal of Clinical Pharmacology, 2026).
This is actually the most practical result from all the literature, as amitriptyline is a preventive medication for migraines and simultaneously the highest-rated option in chronic tension-type headaches. It therefore concerns both groups of people looking for cannabidiol for headaches. The study included 13 people, 12 completed it, and the effect was moderate. The concentration of tramadol did not change, which shows that metabolic inhibition does not work equally on all medications.
It is worth knowing why a measurement in humans matters so much here. A review of the safety of cannabidiol lists the inhibition of cytochrome P450 isoenzymes and drug transporters, but notes that the concentrations in those cell experiments were supraphysiological: to achieve them in the body, oral doses in the range of thousands of milligrams per day would be needed (Iffland and Grotenhermen, Cannabis and Cannabinoid Research, 2017). Therefore, 30 mg, after which the concentration of amitriptyline really increased, weighs more than the enumeration of enzymes. No one has studied triptans with CBD.
The adverse effects of cannabidiol are described more modestly than the popularity of the preparations suggests. A meta-analysis included four randomized studies involving 269 healthy adults, and its primary endpoint was indeed headache: no difference compared to placebo was found. Diarrhea was significantly more common after CBD, although the confidence interval for this result is very wide and ranges from slightly elevated risk to thirtyfold (Sawaira et al., Annals of Medicine and Surgery, 2026). Fatigue, dizziness, and upper respiratory infections did not differ between groups.
Where did the belief that CBD works for migraines come from?
From three sources, none of which is a study of cannabidiol itself in people with migraines. The first is the theory about the endocannabinoid system, the second is an unpublished conference report about a preparation with THC, and the third is user observations of inhaled cannabis.
The theory of clinical endocannabinoid deficiency posits that in some patients, the baseline tension of this system is lowered and that this explains treatment-resistant pain syndromes. Contrary to what is often attributed to it, the author does not leave it in 2016 at the stage of mere assumption: the title of his work states that current studies support this theory, and as objective evidence, he points to statistically significant differences in anandamide concentrations in the cerebrospinal fluid of people with migraines and imaging indicators of reduced system activity in post-traumatic stress disorder (Russo, Cannabis and Cannabinoid Research, 2016). The same direction is independently confirmed by a review of the endocannabinoid system in migraines (Greco et al., Frontiers in Neuroscience, 2018).
However, this is still not an argument for oil. The theory speaks of a deficiency of anandamide, and cannabidiol is not anandamide and does not directly stimulate cannabinoid receptors. The substance that logically follows from this theory would rather be an enzyme inhibitor that breaks down anandamide, and such a target is indicated by the authors of the review.
The Italian report by Nicolodi, cited in the Polish internet as a study, was a conference presentation from 2017. Neither Europe PMC nor Crossref recognize it as a full, peer-reviewed publication, so none of the circulating numbers can be verified at the source. The author herself has other normally published works on migraines in both of these databases, just not this one. Moreover, it tested a preparation combining THC with cannabidiol, not cannabidiol alone.
The third source is an analysis of data from an application in which users recorded symptoms before and after using cannabis: 12,293 sessions with headaches and 7,441 with migraines (Cuttler et al., The Journal of Pain, 2020). The severity of the symptom decreased after use by an average of about half, but there was no control group or placebo, inhaled cannabis was studied, and the authors noted the development of tolerance: effectiveness decreased over time, and doses increased. A detailed breakdown of these works can be found in the text about what studies say about CBD for migraines.
Where to start since CBD has such weak evidence?
From diagnosis, and then from options that have undergone placebo-controlled studies. This is practically the most important part of this article, as it concerns money and time that can easily be spent in the wrong order.
Magnesium has randomized placebo-controlled studies behind it and has made it into national and international recommendations as an option in the prevention of headaches and migraines (Maier et al., Nutrients, 2020). Riboflavin, or vitamin B2, has undergone a meta-analysis of 12 clinical studies involving 749 people and reduced the number of attacks by an average of 1.39 per month, with a dose-dependent relationship up to 400 mg per day (Amini et al., Journal of Research in Medical Sciences, 2026). Heterogeneity between studies was high, so read the result cautiously, but this is a different league of evidence than a series of cases.
In addition, there are triptans in migraine attacks, prevention prescribed by a neurologist, and amitriptyline in chronic tension-type headaches. Magnesium and B vitamin preparations can be found in the supplements category. It is not about discouraging the use of cannabidiol, but about the order: starting with a product without evidence is a costly roundabout.
Frequently Asked Questions
Does CBD help with headaches?
There is no evidence for this. In the first randomized study of cannabis for acute migraine attacks, the arm with a predominance of CBD provided relief after two hours in 53 percent of attacks compared to 47 percent after placebo, and the difference was not statistically significant (Schuster et al., Headache, 2026). The advantage was only shown by the combination of THC with cannabidiol.
How much CBD should I take for a migraine?
No one has established this dosage. There is no clinical study comparing oral cannabidiol doses for migraines or tension-type headaches, so ready-made protocols like “start with 10 mg and increase every three days” are fabricated. The only dose tested in migraines was inhaled and did not outperform placebo.
Does CBD help with tension-type headaches?
No such study has been conducted, so there is simply no answer. In the prevention of chronic tension-type headaches, the highest-rated option in a network meta-analysis of 35 randomized studies was amitriptyline at a dose of 100 mg (Tao et al., Annals of Medicine, 2026). Cannabidiol does not appear in this comparison.
Can CBD be combined with headache medications?
One interaction has been measured in humans. A single dose of 30 mg of CBD increased the concentration of amitriptyline in the plasma of healthy volunteers (Gorbenko et al., British Journal of Clinical Pharmacology, 2026). Amitriptyline is a preventive medication for migraines and tension-type headaches, so consult such a combination with your doctor.
When does a headache require urgent medical attention?
When the pain appears suddenly and is the worst of your life, when accompanied by fever with neck stiffness or neurological deficit, when it occurred after a head injury, when it is the first severe headache after the age of 50, or when it changes its previous character. These signals are collected on the SNNOOP10 list (Do et al., Neurology, 2019).
Can CBD itself cause headaches?
This has not been demonstrated. A meta-analysis of four randomized studies involving 269 healthy adults had headache as the primary endpoint and found no difference compared to placebo; diarrhea was significantly more common after CBD (Sawaira et al., Annals of Medicine and Surgery, 2026). A separate risk remains for headaches from medication overuse.
Certified cannabis oils can be found in the oils category.
This article is for informational and educational purposes and does not constitute medical advice. Before starting to use cannabis or CBD for therapeutic purposes, consult your doctor, especially if you are taking other medications, are pregnant, or breastfeeding.
Author: Michał Waluk · Published: 2026-06-22 · Updated: 2026-08-14
